Compare Enveric Biosciences Inc (ENVB) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Gartner Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Gartner Inc trades at $195.41 (market cap $11.73B). The key difference: Gartner Inc is far larger — about 1753.4× Enveric Biosciences Inc's market cap, and Gartner Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Gartner Inc for 64 Days on average.
| ENVB | IT | |
|---|---|---|
Market Cap | $6.69M | $11.73B |
Volume | 41,141 | 736,899 |
Sector | Health | Technology |
52-Week High | $10.80 | $258.17 |
52-Week Low | $1.27 | $125.68 |
Typical Hold Time | 14 Days | 64 Days |
Enterprise Value | -$1.60M | $13.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Gartner (IT) trades at $185.77, up 0.46% today, showing strong technical momentum with a bullish moving average signal. The company maintains robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and impressive profitability metrics including 69.63% gross margin and 113.58% ROE. Recent news highlights Gartner's leadership position in AI advisory services and strong industry recognition.
While valuation appears reasonable with P/E of 16.71, the stock faces headwinds from negative cash flow trends and a high P/B ratio of 160.06. Analyst consensus is mixed with 27.78% buy ratings but a consensus price target below current levels at $174.63, suggesting limited near-term upside potential despite strong business fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
